Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma:: Study design and preliminary safety results

被引：19
|
作者：
André, T
Colin, P
Louvet, C
Gamelin, E
Bouche, O
Achille, E
Colbert, N
Boaziz, C
Piedbois, P
Tubiana-Mathieu, N
Boutan-Laroze, A
Flesch, M
Billiau, V
Buyse, M
de Gramont, A
机构：
[1] Hop Tenon, Med Oncol Serv, F-75970 Paris 20, France
[2] Hop St Antoine, F-75571 Paris, France
[3] Ctr Paul Papin, Angers, France
[4] CHU Reims, Reims, France
[5] Clin Orangerie, Strasbourg, France
[6] Hop St Joseph, F-75674 Paris, France
[7] Ctr Paris Nord, Sarcelles, France
[8] Hop Henri Mondor, F-94010 Creteil, France
[9] CHU Limoges, Limoges, France
[10] Ctr Hosp Argenteuil, Argenteuil, France
[11] Hop Devron, Dijon, France
[12] Int Inst Drug Dev, Brussels, Belgium
[13] Int Inst Drug Dev, Paris, France
[14] Grp Etud & Rech Clin Oncol Radiotherapy, Paris, France
来源：
SEMINARS IN ONCOLOGY | 2001年 / 28卷 / 01期
关键词：
D O I：
10.1053/sonc.2001.19726
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：35 / 40
页数：6
相关论文
共 50 条
  • [21] Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study
    Qing Zhang
    Hong Chen
    Qin Li
    Yunjin Zang
    Xinguo Chen
    Weilong Zou
    Letian Wang
    Zhong-yang Shen
    Investigational New Drugs, 2011, 29
  • [22] Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study
    Zhang, Qing
    Chen, Hong
    Li, Qin
    Zang, Yunjin
    Chen, Xinguo
    Zou, Weilong
    Wang, Letian
    Shen, Zhong-yang
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (06) : 1360 - 1369
  • [23] Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients.
    Andre, T
    Quinaux, E
    Louvet, C
    Gamelin, E
    Bouche, O
    Achille, E
    Piedbois, P
    Tubiana-Mathieu, N
    Buyse, M
    de Gramont, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 251S - 251S
  • [24] FOLINIC ACID DOES IMPROVE 5-FLUOROURACIL ACTIVITY INVIVO - RESULTS OF A PHASE-III STUDY COMPARING 5-FLUOROURACIL TO 5-FLUOROURACIL AND FOLINIC ACID IN ADVANCED COLON CANCER-PATIENTS
    BOBBIOPALLAVICINI, E
    PORTA, C
    MORONI, M
    SPAGHI, A
    CASAGRANDA, I
    NASTASI, G
    JOURNAL OF CHEMOTHERAPY, 1993, 5 (01) : 52 - 55
  • [25] Randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP, 5-FU and dl-leucovorin for advanced colorectal cancer
    Okabe, S
    Arai, T
    Yamashita, H
    Sugihara, K
    Sasaki, T
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (01) : 56 - 62
  • [26] Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National surgical adjuvant breast and bowel project protocol C-05
    Wolmark, N
    Bryant, J
    Smith, R
    Grem, J
    Allegra, C
    Hyams, D
    Atkins, J
    Dimitrov, N
    Oishi, R
    Prager, D
    Fehrenbacher, L
    Romond, E
    Colangelo, L
    Fisher, B
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (23) : 1810 - 1816
  • [27] A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: The Pan-European Trial in Adjuvant Colon Cancer 2 study
    Koehne, Claus-Henning
    Bedenne, Laurent
    Carrato, Alfredo
    Bouche, Olivier
    Popov, Ivan
    Gaspa, Losa
    Valladares, Manuel
    Rougier, Phillipe
    Gog, Christiane
    Reichardt, Peter
    Wils, Jacques
    Pignatti, Francesco
    Biertz, Frank
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (08) : 1868 - 1875
  • [28] A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer - A Hellenic Cooperative Oncology Group (HeCOG) study
    Kalofonos, HP
    Nicolaides, C
    Samantas, E
    Mylonakis, N
    Aravantinos, G
    Dimopoulos, MA
    Gennatas, C
    Kouvatseas, G
    Giannoulis, E
    Dervenis, C
    Basdanis, G
    Pavlidis, N
    Androulakis, I
    Fountzilas, G
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (01): : 23 - 30
  • [29] Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer
    Allegra, C. J.
    Yothers, G.
    O'Connell, M. J.
    Sharif, S.
    Wolmark, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.
    Flejou, Jean-Francois
    Andre, Thierry
    Chibaudel, Benoist
    Scriva, Aurelie
    Hickish, Tamas
    Tabernero, Josep
    Van Laethem, Jean-Luc
    Banzi, Maria
    Maartense, Eduard
    Shani, Adi
    Carlsson, Goeran
    Scheithauer, Werner
    Papamichael, Demetris
    Moehler, Markus
    Landolfi, Stefania
    Demetter, Pieter
    Duval, Alex
    Lee, Mark
    Colote, Soudhir
    De Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345